Jade Biosciences (JBIO) Accumulated Expenses (2020 - 2026)

Jade Biosciences' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $14.9 million for Q1 2026.

• Quarterly Accumulated Expenses rose 629.47% year-over-year to $14.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.9 million (up 629.47% YoY) and the FY2025 annual result came in at $9.4 million, up 128.34% from the prior year.
• Accumulated Expenses was $14.9 million for Q1 2026 at Jade Biosciences, up from $9.4 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $14.9 million in Q1 2026 and bottomed at $817000.0 in Q2 2022.
• A 5-year average of $7.1 million and a median of $7.7 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses surged 802.82% — and 2025, when it tumbled 79.12%.
• Jade Biosciences' Accumulated Expenses stood at $2.8 million in 2022, then jumped by 240.35% to $9.4 million in 2023, then sank by 55.94% to $4.1 million in 2024, then soared by 128.34% to $9.4 million in 2025, then surged by 57.68% to $14.9 million in 2026.
• Business Quant data shows JBIO's Accumulated Expenses at $14.9 million in Q1 2026, $9.4 million in Q4 2025, and $14.0 million in Q3 2025.